MCM6 Inhibitors

MCM6 inhibitors, as described here, encompass a range of chemical agents that target various stages of DNA replication and repair, indirectly affecting the function of the MCM6 protein. These inhibitors include nucleoside analogs, DNA synthesis inhibitors, and agents that induce DNA damage, each playing a role in impeding the normal function of the MCM complex, of which MCM6 is a part., Nucleoside analogs, like Gemcitabine and Fludarabine, are incorporated into DNA during replication, leading to chain termination and consequently, disrupting the replication process. This mechanism indirectly affects the MCM complex, as it impedes the progression of replication forks, where the MCM complex plays a pivotal role. Similarly, inhibitors like Hydroxyurea and 5-Fluorouracil reduce the availability of nucleotides necessary for DNA synthesis, indirectly influencing the MCM complex's activity. On the other hand, agents such as Cisplatin and Camptothecin induce DNA damage. Cisplatin forms DNA crosslinks, while Camptothecin inhibits topoisomerase I, preventing the relaxation of DNA supercoils during replication. These forms of DNA damage can stall replication forks, indirectly impacting the MCM complex's function in unwinding DNA helices for replication. Etoposide, another topoisomerase inhibitor, but targeting topoisomerase II, induces DNA strand breaks, further contributing to replication stress. Furthermore, compounds like Palbociclib and Bortezomib disrupt cell cycle progression. Palbociclib, a CDK4/6 inhibitor, halts cells in the G1 phase, preventing the initiation of DNA replication, where the MCM complex is crucial. Bortezomib, a proteasome inhibitor, leads to cell cycle arrest and can interfere with the regulation of proteins involved in DNA replication and repair.